It looks like over the long weekend somebody discovered that the median survival for NSCLC adenocarcinoma is likely to at least double using ganetespib + docetaxel. The world has 600,000 NSCLC adenocarcinoma patients/yr. Synta owns all the rights to ganetespib. Synta's market cap is still
The only person who would be disappointed by the initial phase II data would be a completely clueless #$%$ who thought that Ganetespib would be approved in 6 months. What was truly amazing is that there actually was some imbecile who repeatedly posted that on this board about 3 months ago. Does this ring a bell for you?